Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
Legend Biotech Corp ADR (NASDAQ: LEGN) closed the day trading at $19.01 down -1.71% from the previous closing price of $19.34. In other words, the price has decreased by -$1.71 from its previous closing price. On the day, 3.06 million shares were traded. LEGN stock price reached its highest trading level at $19.855 during the session, while it also had its lowest trading level at $18.99.
Ratios:
For a better understanding of LEGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.80 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.26.
On January 07, 2026, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $75.
On October 07, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $40.Cantor Fitzgerald initiated its Overweight rating on October 07, 2025, with a $40 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 26 ’25 when Huang Ying bought 64,339 shares for $22.52 per share.
Sanders Corazon (Corsee) D. bought 969 shares of LEGN for $22,064 on Dec 24 ’25. On Dec 24 ’25, another insider, Huang Ying, who serves as the Officer of the company, bought 61,467 shares for $22.95 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 3510948608 and an Enterprise Value of 6439544320. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.86 while its Price-to-Book (P/B) ratio in mrq is 3.47. Its current Enterprise Value per Revenue stands at 7.084 whereas that against EBITDA is -35.53.
Stock Price History:
The Beta on a monthly basis for LEGN is 0.11, which has changed by -0.48116815 over the last 52 weeks, in comparison to a change of 0.15024745 over the same period for the S&P500. Over the past 52 weeks, LEGN has reached a high of $45.30, while it has fallen to a 52-week low of $19.21. The 50-Day Moving Average of the stock is -22.52%, while the 200-Day Moving Average is calculated to be -40.35%.
Shares Statistics:
Over the past 3-months, LEGN traded about 2.26M shares per day on average, while over the past 10 days, LEGN traded about 3617000 shares per day. A total of 184.69M shares are outstanding, with a floating share count of 180.91M. Insiders hold about 2.05% of the company’s shares, while institutions hold 44.61% stake in the company. Shares short for LEGN as of 1767139200 were 17773269 with a Short Ratio of 7.86, compared to 1764288000 on 14235758. Therefore, it implies a Short% of Shares Outstanding of 17773269 and a Short% of Float of 18.39.
Earnings Estimates
. The current rating of Legend Biotech Corp ADR (LEGN) is the result of assessments by 2.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.07 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.86 and -$1.64 for the fiscal current year, implying an average EPS of -$1.41. EPS for the following year is $0.25, with 3.0 analysts recommending between $0.64 and -$0.04.
Revenue Estimates
12 analysts predict $310.02M in revenue. The current quarter. It ranges from a high estimate of $362.17M to a low estimate of $287.98M. The current estimate, Legend Biotech Corp ADR’s year-ago sales were $186.52MFor the next quarter, 12 analysts are estimating revenue of $321.82M. There is a high estimate of $378.75M for the next quarter, whereas the lowest estimate is $301.83M.
A total of 15 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $1.08B, while the lowest revenue estimate was $1.01B, resulting in an average revenue estimate of $1.03B. In the same quarter a year ago, actual revenue was $627.24MBased on 15 analysts’ estimates, the company’s revenue will be $1.49B in the next fiscal year. The high estimate is $1.68B and the low estimate is $1.31B.
